Publication | Closed Access

Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells

InflammationChronic Inflammatory DiseasesImiquimod-induced Psoriasis-like InflammationCytokineAnti-inflammatoryMedicineImmunologyChronic InflammationTherapeutic TreatmentInflammatory MediatorsDermatologyImmunotherapyPsoriatic Arthritis